1. Home
  2. TKLF vs MBAI Comparison

TKLF vs MBAI Comparison

Compare TKLF & MBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TKLF

Yoshitsu Co. Ltd

HOLD

Current Price

$1.81

Market Cap

8.3M

ML Signal

HOLD

Logo Check-Cap Ltd. Ordinary Share

MBAI

Check-Cap Ltd. Ordinary Share

HOLD

Current Price

$1.35

Market Cap

8.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
TKLF
MBAI
Founded
2006
2004
Country
Japan
Israel
Employees
N/A
N/A
Industry
Other Specialty Stores
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
8.3M
8.8M
IPO Year
2020
2014

Fundamental Metrics

Financial Performance
Metric
TKLF
MBAI
Price
$1.81
$1.35
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
14.5K
52.2K
Earning Date
12-19-2025
05-12-2026
Dividend Yield
10.97%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.82
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.76
$0.95
52 Week High
$4.32
$3.92

Technical Indicators

Market Signals
Indicator
TKLF
MBAI
Relative Strength Index (RSI) 42.79 55.81
Support Level $1.78 $0.99
Resistance Level $2.43 $1.83
Average True Range (ATR) 0.10 0.11
MACD -0.02 0.05
Stochastic Oscillator 37.44 60.69

Price Performance

Historical Comparison
TKLF
MBAI

About TKLF Yoshitsu Co. Ltd

Tokyo Lifestyle Co Ltd is a retailer and wholesaler of Japanese beauty and health products, sundry products, electronic products, and other products. It sells its products through directly operated physical stores, online stores, and franchise stores and wholesale customers. It operates through directly operated physical stores, online stores and services, and franchise stores and wholesale customers segments, with the franchise stores and wholesale customers segment generating maximum revenue. Geographically, it generates maximum revenue from Hong Kong.

About MBAI Check-Cap Ltd. Ordinary Share

Check-Cap Ltd is a clinical-stage medical diagnostics company engaged in the development of an ingestible imaging capsule that utilizes low-dose X-rays for the detection and imaging of colonic polyps and colorectal cancers, or CRC. The company is developing C-Scan, the first capsule-based system for preparation-free, colorectal cancer screening. Its scanning capsule will be swallowed and propelled by natural motility through the gastrointestinal tract and excreted naturally with no need for retrieval for data collection. The operations of the company are presently located in Israel, but plans to market products in the United States, Europe, Israel and Japan.

Share on Social Networks: